GRI Bio (GRI) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GRI Bio is the larger company by market cap ($2.4 million vs $2.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | LABT |
|---|---|---|
| Share price | $1.12 | $0.2449 |
| Market cap | $2.45M | $2.19M |
| 1-day change | 0.00% | +15.03% |
| P/E ratio (TTM) | 0.05 | — |
| EPS (TTM) | $20.57 | $-5.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-11.96M | — |
| 52-week high | $64.12 | $98.20 |
| 52-week low | $1.09 | $0.17 |
| Distance from 52-week high | -98.25% | -99.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1551.79% | +4799.96% |
| Average volume | 218.31K | 16.14M |
| Shares outstanding | 2.19M | 8.95M |
| Employees | 3 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
GRI vs LABT FAQ
Which is bigger, GRI Bio or Lakewood-Amedex Biotherapeutics?
GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $2.19M for Lakewood-Amedex Biotherapeutics (LABT).
Are GRI Bio and Lakewood-Amedex Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.